{"id":6753,"date":"2021-02-18T20:17:32","date_gmt":"2021-02-18T12:17:32","guid":{"rendered":"http:\/\/zestmag.com\/online\/?p=6753"},"modified":"2021-02-23T17:29:28","modified_gmt":"2021-02-23T09:29:28","slug":"astrazenecas-dapagliflozin-now-approved-to-treat-adult-patients-with-heart-failure-in-phl","status":"publish","type":"post","link":"http:\/\/zestmag.com\/online\/astrazenecas-dapagliflozin-now-approved-to-treat-adult-patients-with-heart-failure-in-phl\/","title":{"rendered":"AstraZeneca\u2019s Dapagliflozin now approved to treat adult patients with heart failure in Phl"},"content":{"rendered":"\n

Dapagliflozin, a medicine developed by British-Swedish pharmaceutical company AstraZeneca, is now approved in the Philippines for the treatment of adult patients suffering from heart failure with reduced ejection fraction (HFrEF) to reduce the need for hospitalization and risk of mortality.<\/strong><\/p>\n\n\n\n

With the approval, Dapagliflozin is the first and only drug under the sodium glucose transport protein 2 inhibitor (SGLT2i) class approved to treat heart failure in adult patients with reduced ejection fraction. It is the only SGLT2i proven to significantly prevent cardiovascular death and death due to other causes in these heart failure patients.<\/p>\n\n\n\n

In a virtual discussion hosted by AstraZeneca Philippines, experts from the Philippines and around the world talked about the latest medical development and treatment for heart failure.<\/p>\n\n\n\n

According to Dr. Erlyn Demerre, chair of Heart Failure Program at St. Luke\u2019s Medical Center in Quezon City, heart failure is dominating the cardiovascular landscape not just in the Philippines but globally. It is considered a global pandemic affecting a lot of people worldwide and it is increasing in prevalence.<\/p>\n\n\n\n

Global data show that the overall known prevalence rate of heart failure is three to 20 patients per 1,000 population although this exceeds a 100 per 1,000 in those age 65 years and over. The annual incidence of heart failure is one to five per 1,000 and the relative incidence doubles for each decade of life after the age of 45, and that in one in three die within a year and one out of four are re-admitted in a hospital in 30 days with much morbidity and poor quality of life.<\/p>\n\n\n\n

\u201cIt is still an ongoing pandemic. Much work has been put into the study of heart failure and we are definitely on a better position in the diagnosis and management of heart failure now. But, ironically, despite medical management and significant advance in therapies and prevention, heart failure is still a major and increasing burden all over the world with high mortality and morbidity and poor quality of life,\u201d said Demerre.  <\/p>\n\n\n\n

Lotis Ramin, country president at AstraZeneca Philippines, relayed that nine out of 10 patients are symptomatic even with current heart failure standard of care (SoC), and nearly one-third or one out of three patients suffering from heart failure with reduced ejection fraction are at risk of hospitalization which increases the risk of mortality.<\/p>\n\n\n\n

Professor David Sim, president of the Heart Failure Society in Singapore, noted that nine million people in Southeast Asia have heart failure with an overall 15% mortality rate. However, pharmacological options for heart failure have increased over the last decade and guideline-directed heart failure pharmacotherapy cumulatively reduced mortality by 76%. <\/p><\/blockquote>\n\n\n\n

Sim emphasized that \u201cthe approval of Dapagliflozin for the treatment of HFrEF in the Philippines is a major step forward in the battle against the disease burden of heart failure. Together with the current standard of care, Dapagliflozin will contribute further to a lower mortality, less hear failure hospitalization and importantly a better quality of life for patients suffering from heart failure.\u201d<\/p>\n\n\n\n

In his presentation on Dapagliflozin and Prevention of Adverse-outcomes in Heart Failure Trial (DAPA HF) Trial: A New Era in Heart Failure Management, Professor Piotor Ponikowski of the Heart Failure Association of the European Society of Cardiology cited that \u201cheart failure is becoming a preventable and treatable diseases, with medication that allows patients to live longer and live better outside of hospital.\u201d<\/p>\n\n\n\n

It is the first outcomes trial with an SGLT2 inhibitor investigating the treatment of HFrEF. The results showed a reduction of 26% in the occurrence of cardiovascular death, hospitalization for heart failure (hHF) and Urgent Hospital Visit for heart failure along with a 30% reduction in hHF. Dapagliflozin\u2019s significant 18% reduction in cardiovascular death and 17% reduction on death due to other causes which were only seen in the DAPA HF study.<\/p>\n\n\n\n

\u201cDapagliflozin has the ability to reduce mortality, prevent hospital admission, improve clinical status, functional capacity, and quality of life,\u201d said Ponikowski.<\/p>\n\n\n\n

With the confirmation of Dapagliflozin as a medication to treat adult persons suffering from heart failure with reduced ejection fraction, Ramin said \u201cwe hope this development and Dapagliflozin life-saving efficacy can transform the heart failure standard of care.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"

Dapagliflozin, a medicine developed by British-Swedish pharmaceutical company AstraZeneca, is now approved in the Philippines for the treatment of adult patients suffering from heart failure.<\/p>\n","protected":false},"author":14,"featured_media":6769,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[16],"tags":[1260,806,2357,1756,694,2200,1261,1538,1016,1015,2242,303],"class_list":["post-6753","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-product-showcase","tag-good-heart","tag-health-products","tag-healthy-products","tag-heart-attack","tag-heart-disease","tag-heart-failure","tag-heart-health","tag-medical-care","tag-medication","tag-medicine","tag-product-showcase","tag-sustainable-products"],"_links":{"self":[{"href":"http:\/\/zestmag.com\/online\/wp-json\/wp\/v2\/posts\/6753","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/zestmag.com\/online\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/zestmag.com\/online\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/zestmag.com\/online\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"http:\/\/zestmag.com\/online\/wp-json\/wp\/v2\/comments?post=6753"}],"version-history":[{"count":3,"href":"http:\/\/zestmag.com\/online\/wp-json\/wp\/v2\/posts\/6753\/revisions"}],"predecessor-version":[{"id":6758,"href":"http:\/\/zestmag.com\/online\/wp-json\/wp\/v2\/posts\/6753\/revisions\/6758"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/zestmag.com\/online\/wp-json\/wp\/v2\/media\/6769"}],"wp:attachment":[{"href":"http:\/\/zestmag.com\/online\/wp-json\/wp\/v2\/media?parent=6753"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/zestmag.com\/online\/wp-json\/wp\/v2\/categories?post=6753"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/zestmag.com\/online\/wp-json\/wp\/v2\/tags?post=6753"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}